The overall group closes 2022 with a profit in the double-digit million range. The company again succeeded in significantly topping the average sales growth of 3.3 percent in the medical technology sector as determined in the BVMed autumn survey*. “Thanks to the consistent implementation of our sustainable business development strategy and our high-quality products, which users value, as well as the high level of commitment shown by all our employees, we have succeeded in continuing on our growth path,” says Chief Executive Officer Klaus Kiesel. Christoph Ulrich, Managing Partner of ulrich medical, adds: “We are proud of the result and look positively towards the new business year. With the unrestricted supply capability of our products, we are and will remain a reliable partner for our customers in 2023.”
ulrich medical increases sales by 12 percent
Introduction: The Ulm-based medical technology manufacturer is again reporting significant growth for 2022: at around 136 million euros, the company was able to increase its sales by 12 percent compared to the previous year.
CEO Klaus Kiesel (left) and Managing Director Christoph Ulrich (right), pictured in the production area of ulrich medical, are proud of the results of fiscal year 2022.
About ulrich medical
ulrich GmbH & Co. KG, ulrich medical for short, develops, manufactures and distributes products for spinal surgery and contrast media injectors. Founded in 1912, the family business employs a total of around 600 people at its headquarters in Ulm and its three subsidiaries in France, Spain and the USA. While its products are used all over the world, the medical technology company relies on quality “Made in Germany,” making it one of the few in the industry that consistently develops and manufactures its products in Germany. The F.A.Z. Institute named ulrich medical one of Germany's “Innovation Leaders” for the fifth time in a row in 2023.
